Hims & Hers for compounded ED treatments.

• Telehealth Services: Connects consumers to licensed healthcare professionals for virtual consultations, with an initial focus on men's wellness and erectile dysfunction.
• Online Pharmacy Access: Provides customers access to a licensed pharmacy for online fulfillment and distribution of prescribed medications.
• Mango ED Product: A compounded, rapid-dissolve sublingual tablet for erectile dysfunction, containing Tadalafil, Oxytocin, and L-Arginine.

Mangoceuticals (MGRX) sells primarily to **individuals** through its website, www.MangoRX.com, offering men's wellness telemedicine services and products. Based on the provided description, the company serves the following categories of customers:

1. Men experiencing Erectile Dysfunction (ED): This is the primary target demographic for their "Mango" ED product, aimed at addressing a condition estimated to affect a significant portion of the male population.

2. Men seeking enhanced sexual vitality and performance: The company also positions itself as a lifestyle brand for men looking to improve their sexual health beyond just clinical ED, focusing on vitality and performance.

3. Men interested in overall mood and confidence improvements related to sexual health: As part of its lifestyle branding, Mangoceuticals targets men who seek better mood and confidence, recognizing the link between sexual health and overall well-being.

Jacob D. Cohen - Chief Executive Officer and Chairman

Jacob D. Cohen is a serial entrepreneur with over 20 years of experience in investment banking and capital markets, having started and grown multiple companies across various sectors, including marketing, advertising, healthcare, IT, and financial services. Prior to co-founding Mangoceuticals, Inc., he was a co-founder and managing partner of several boutique investment bank and strategic advisory firms, where he advised companies on raising capital in both private and public markets. He previously served as the Chief Financial Officer of The Renewed Group, Inc. from 2010 through 2013, and as Executive Vice President and Controller of Metiscan, Inc. from 2008 to 2010, where he restructured and operated the company and its subsidiaries and raised over $8 million in equity financing. He was also President and Chief Executive Officer of Shoreline Employment Services, Inc., a Metiscan subsidiary. Mr. Cohen is also the CEO of Cohen Enterprises, Inc., which acquired control of MGRX in 2022, and Ronin Equity Partners, Inc., both private investment companies.

Eugene M. Johnston - Chief Financial Officer

Eugene M. Johnston was appointed as Chief Financial Officer of Mangoceuticals, Inc. on October 1, 2022. In this role, he is responsible for the company's financial planning, risk management, and reporting, overseeing all financial activities, including budgeting, forecasting, and investment strategies. He possesses extensive expertise in corporate finance, accounting, and capital markets, gained through a distinguished career in the financial sector where he held senior financial positions at prominent organizations before joining Mangoceuticals.

Amanda Hammer - Chief Operating Officer

Amanda Hammer joined the MangoRx team in late 2022 and has been instrumental in launching and optimizing MangoRx's e-commerce platform. She oversees the company's day-to-day administrative and operational functions, bringing a wealth of experience in operational management, process optimization, and team leadership. Prior to Mangoceuticals, she had a four-year tenure at D Magazine Partners, a Dallas-based multimedia company, where she rose to become the company's first Chief Operations Officer.

Antonios Isaac - President and Director

Antonios Isaac serves as President and a Director of Mangoceuticals, Inc. In his capacity as President, he plays a pivotal role in guiding the company's operational direction and fostering its growth initiatives, and as a Director, he contributes to strategic decision-making and corporate governance. His leadership focuses on driving operational efficiency and fostering strategic partnerships.

Jonathan Arango - Director

Jonathan Arango serves as a Director of Mangoceuticals, Inc. He plays a multifaceted role, contributing significantly to the company's governance and strategic direction, which includes corporate governance, legal compliance, and the execution of strategic initiatives.

Key Risks to Mangoceuticals (MGRX)

• Regulatory Non-Compliance and Product Safety: Mangoceuticals' "Mango" ED product has not been, and will not be, approved by the FDA. Instead, the company plans to produce and sell its products under an exemption provided by Section 503A of the Federal Food, Drug, and Cosmetic Act. The company states it is not aware of any clinical studies involving the sublingual administration of tadalafil at the doses they provide or the compounding of tadalafil, oxytocin, and L-arginine to treat ED, as contemplated by their product. The absence of FDA approval means the product has not benefited from the FDA’s clinical trial protocol, which seeks to prevent serious patient injury and death, exposing the company to significant risks of costly litigation, governmental action, fines, judgments, or penalties.
• Intense Competition and Product Replicability: The company explicitly states that because its Mango ED product is specially compounded for the customer with publicly disclosed ingredients, the product formula can be replicated by other companies. Mangoceuticals is also aware of other companies currently selling oral disintegrating tablets for ED, some using a combination of Tadalafil and Sildenafil, indicating a competitive market that could challenge their ability to gain and maintain market share.
• Limited Operating History and Nominal Revenues: Mangoceuticals launched its website in mid-November 2022 and planned to market and seek to sell commercial quantities of its Mango ED product in the first quarter of 2023. To date, the company has sold only a small amount of products and generated only nominal revenues, highlighting the risks associated with an early-stage company that has not yet established significant market traction or a consistent revenue stream.

The addressable markets for Mangoceuticals' main products and services in the U.S. are as follows:

• Erectile Dysfunction (ED) Drugs Market: The U.S. erectile dysfunction drugs market was valued at approximately USD 1.09 billion in 2024 and is projected to reach around USD 2.55 billion by 2034, demonstrating a compound annual growth rate (CAGR) of 8.87% from 2025 to 2034.
• Telemedicine Market: The U.S. telemedicine market size was valued at USD 81 billion in 2024. This market is anticipated to expand from USD 94.3 billion in 2025 to USD 395.6 billion by 2034, with a CAGR of 17.3%.

Expected Revenue Growth Drivers for Mangoceuticals (MGRX)

1. Growth in customers utilizing the MangoRX.com telehealth platform and associated pharmacy services: Mangoceuticals plans to connect consumers to licensed healthcare professionals via its recently launched website, MangoRX.com, for telehealth consultations and access to a licensed pharmacy for online fulfillment of prescribed medications. Increased adoption of these telehealth services is expected to drive customer growth and associated revenue.
2. Successful commercialization and sales growth of the "Mango" Erectile Dysfunction (ED) product: The company has developed and is actively preparing to commercially market its new "Mango" ED product. With anticipated marketing and operational investments, increased sales volume of this product, available in two dosage levels and compounded under Section 503A of the FD&C Act, is a key expected driver of revenue growth.
3. Expansion of brand positioning as a lifestyle company for men's sexual vitality and overall well-being: Beyond treating ED, Mangoceuticals aims to brand itself as a lifestyle company targeting men seeking enhanced sexual vitality, performance, and overall mood and confidence. This broader market appeal and branding strategy could attract a wider customer base and drive revenue growth.
4. Increased market penetration within the growing men's wellness telemedicine sector: Mangoceuticals has identified men’s wellness telemedicine services and products, particularly those related to ED, as a growing sector. The company's strategic focus on this expanding market segment and its online-exclusive sales model via MangoRX.com are expected to contribute to increased market share and revenue.

Share Issuance

• Mangoceuticals anticipates using approximately $1.8 million of the net proceeds from an offering to finance marketing and operational expenses for its Mango ED product.